Genomic medicines firm Ensoma announced the closure of its Series B financing extension, garnering an additional $50 million.
This funding brings the total round to $135 million. New investors Kite (a Gilead Company), Bioluminescence Ventures, and Delos Capital contributed to this extension, alongside existing investor SymBiosis.
Ensoma is developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system.
The company is set to advance the development of its Engenious™ in vivo engineered cell therapy platform and a pipeline of genomic medicines, targeting immuno-oncology, genetic disease, and other therapeutic applications.
“Ensoma is creating a new generation of smart immune cell medicines by harnessing the concerted power of multiple immune cell types,” said Ensoma CEO, Emile Nuwaysir, Ph.D. “With this financing, we are well positioned to bring our breakthrough therapies to the clinic.”
Dr. Kouki Harasaki, managing partner at Bioluminescence Ventures, will join Ensoma’s Board of Directors following the extension financing.
Other notable investors in the Series B include the Bill & Melinda Gates Foundation, Takeda Ventures, and Viking Global Investors.
“Ensoma’s Engenious platform brings together delivery and engineering capabilities to unlock the full promise of in vivo multiplexed therapies. We are very excited about working with the Ensoma team to make this a reality,” Harasaki said.